flatiron abstraction test

naar Posted by Flatiron School/November 30, 2022. Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features. In July 2015, I joined Flatiron Health as a clinical abstraction manager for the breast, melanoma and hematology teams. 2022 was a year of exciting growth and impact for #ClinicalResearch at Flatiron Health! Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: are some patients missing out? Rates of systemic anticancer therapy (SACT) for advanced non-small cell lung cancer (aNSCLC) in the U.S. 2011-2018. #2023builtinbest #flatironhealth #lifeatflatiron", 100 Best Places to Work in 2023 | Built In. Dr Atlas is supported by grant 18SFRN34250007 from the . Received an email with a link to an assessment. The Clinical Registry Abstractor 's (CRA) chief responsibility is to abstract clinical process/outcome measure data and related information from the clinical record for the assigned patient encounters. Disclaimer: The information in this blog is current as of 01 Dec 2022. How much do you all pay in premiums? The assessment itself is ridiculous. Its completely contradictory. 1 (888) 958-0569, By continuing your journey on our site, you consent to the placement of cookies. To handle volume adjustments, we use a . The test is a good indicator of strategic thinking, how quickly you pick up new concepts and how well you cope under pressure. We officially launched our Clinical Research business, joined. I was wondering what other institutions benefit packages are. Gemcitabine and nab-paclitaxel in older adults with metastatic pancreatic cancer: are two doses per cycle enough? I interviewed at Flatiron Health. The VIBE awards are based on anonymously-submitted feedback from current employees from over 400 companies across the country so it speaks volumes about how our people, as a community, feel about working at Flatiron we couldnt be more proud! Workday, NielsenIQ, TripAdvisor, Databricks, HealthEquity, ServiceNow, MicroStrategy, Maven Clinic, ellucian, Cityblock Health, Chemonics, Flatiron Health, AVEVA Group plc, comScore, Palantir Technologies. The area of focus pertained to: Problem decomposition, algorithms for data analysis, abstraction design, and ethics in computing. You also have the option to opt-out of these cookies. Part-Time Oncology Abstractor (Current Employee) - Remote - December 9, 2022. Please help us protect Glassdoor by verifying that you're a Real-world treatment patterns and survival in patients (pts) with hepatocellular carcinoma in the United States, Real-world patterns of care among patients with metastatic pancreatic cancer (mPC), Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients, Real-world rates of hematology lab abnormalities and associated cost among metastatic pancreatic cancer (mPC) therapeutic regimens, Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts), Real-world outcomes of first-line U.S. patients with unresectable advanced or metastatic gastroesophageal adenocarcinoma by primary tumor location, Cancers with NTRK gene fusions: molecular characteristics and prognosis, Utility of novel clinico-genomic data to understand patient characteristics, treatments, and outcomes according to PIK3CA mutation status among hormone receptor positive metastatic breast cancer patients, Real-world predictors of first-line treatment and descriptive outcomes in patients with HR+/HER2- metastatic breast cancer in the US, Initial real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+HER2-metastatic breast cancer, Treatment sequencing of HR+/HER2- metastatic breast cancer (mBC) patients based on PIK3CA alteration status a retrospective analysis of a US clinicogenomics database, Systemic corticosteroid use in patients with metastatic triple-negative breast cancer treated with first-line therapy in the United States, Visualization of the relationship between survival and sequential treatments in metastatic breast cancer, Cardiac events in patients with HER2-positive metastatic breast cancer who have low left ventricular ejection fraction prior to initiating treatment with ado-trastuzumab emtansine: a retrospective cohort study using electronic health record data, Use of pertuzumab in combination with taxanes for HER2+ metastatic breast cancer: analysis of U.S. electronic health records, Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy, Overall survival for first-line palbociclib plus letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice, Characteristics of MBC patients receiving first line treatments in the US real-world setting in the era of CDK4/6 inhibitors, Cell of origin (COO) association with high body mass index (BMI) and overall survival (OS) in patients with diffuse large b-cell lymphoma (DLBCL), Approximating international myeloma working group uniform response criteria to derive response for multiple myeloma (MM) patients using data from electronic health records (EHR), Trends in the multiple myeloma treatment landscape: a United States analysis of Oscer electronic health record data 2011-2019, Utilization and early discontinuation of first-line ibrutinib for patients with chronic lymphocytic leukemia treated in the community oncology setting in the United States, Real-world application of National Comprehensive Cancer Network (NCCN) testing guidelines in diffuse large B-cell lymphoma (DLBCL) results in underdiagnosis of double-hit lymphoma, Real-world outcomes of patients with relapsed/refractory diffuse large B cell lymphoma who receive commercially-available salvage therapy, Evolving real-world treatment patterns in patients with newly-diagnosed multiple myeloma (NDMM) in the United States (U.S.), Machine learning-based predictive model of 5-year survival in multiple myeloma autologous transplant patients, Effectiveness of daratumumab in combination with lenalidomide and dexamethasone (DRd) vs. common standard-of-care regimens in patients with non-transplant newly diagnosed multiple myeloma (NDMM), Brain metastases, treatment patterns, and outcomes in ROS1-positive NSCLC patients from US oncology community centers, Methodological approaches for incorporating real-world data (RWD) for overall survival (OS) into long-term survival estimates: a case-study nice technology appraisal in extensive-stage small-cell lung cancer (ES-SCLC), A landmark response analysis to determine cost-effectiveness of third-line nivolumab for small cell lung cancer, A partitioned survival model to determine cost-effectiveness of third-line nivolumab monotherapy for small cell lung cancer, A comparison of patient characteristics treated with nivolumab for recurrent/metastatic (r/m) squamous cell carcinoma of the head and neck (SCCHN) in Germany and the USA, Real-world treatment patterns of patients with recurrent/metastatic head and neck squamous cell carcinoma who were eligible for second-line therapy after platinum-based chemotherapy, Real-world survival and treatment patterns of patients with recurrent/metastatic head and neck squamous cell carinoma who were eligible for first-line therapy, Medicaid expansion and racial inequities in next-generation sequencing testing in oncology, Cancer immunotherapy use and effectiveness in real-world patients living with HIV, Real-world outcomes associated with the use of companion diagnostics in NSCLC, Flatiron Health 2011-2018, Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma, Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis, Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC), Treatment patterns and outcomes for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice, Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices, Use of trastuzumab emtansine (T-DM1) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world, Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients, Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies, Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset, Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC), Analysis of tumor mutational burden, cancer immunotherapy use, and outcomes based on genomic ancestry in non-small cell lung cancer patients treated in community practice in the United States, Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET), LKB1 mutations in metastatic non-small cell lung cancer (mNSCLC): Prognostic value in the real world, Real-world treatment patterns and survival in non-small cell lung cancer patients with EGFR exon 20 insertion mutations, Real-world treatment patterns and outcomes in ALK+ NSCLC patients receiving immuno-oncology therapy in the United States, Pembrolizumab for previously treated PD-L1-expressing advanced NSCLC: Real-world time on treatment and overall survival, Real-world trends in systemic therapy for nonsquamous EGFR/ALK-negative advanced NSCLC (aNSCLC) in the U.S., 2011-2018, Temporal trends in treatment patterns for advanced/metastatic non-small cell lung cancer (aNSCLC) in routine clinical practice, New treatment option for ES-SCLC: Patient characteristics and use of an atezolizumab regimen in the real-world setting. Proton beam therapy (PBT) is a potentially superior technology to photon radiotherapy for tumors with complex anatomy, tumors surrounded by sensitive tissues, and childhood cancers. When you choose to start a program at Flatiron School, we know that you are investing both financially and an investment of your time. Flatiron School's immersive courses aim to launch students into fulfilling careers by providing a robust career services framework . Experience from Electronic Health Records (EHR), Olaratumab for the Treatment of Patients (pts) with Advanced/Metastatic Soft Tissue Sarcoma (STS): Treatment Patterns in the United States (US) During the First Year Post-Approval, Emergent Renal and Hepatic Dysfunction (dys) in a Real-World Cohort of Advanced Melanoma (aMel) Patients (pts) Receiving First Line (1L) Immune Checkpoint Inhibitors (ICIs), Real World Outcomes of Metastatic Pancreatic Cancer (mPC) Patients (pts) Treated with Liposomal Irinotecan (nal-IRI) in the US, Impact of Flexible Assessment Schedules on Treatment Effect Bias in Pragmatic Clinical Trials, Sequencing of Ramucirumab (ram) and Immune Checkpoint Inhibitors (ICIs) in Platinum (Pt)-Treated Real-World Patients (pts) with Advanced Non-Small Cell Lung Cancer (aNSCLC), Identifying the Prognostic Significance of Genomic Alterations in a Real-World, EHR-Derived Clinico-Genomic Database (CGDB), Prevalence of Microsatellite Instability and Association with Pembrolizumab (P) Usage in a Real-World Clinico-Genomic Database, Ramucirumab (ram), Immune Checkpoint Inhibitors (ICIs), and Single-Agent Chemotherapy (chemo) Usage in Real-World Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients (pts) after Rapid Disease Progression (RDP) on Platinum (Pt), ICD-Coded Information on Sites of Metastasis in Oncology Real-World Data is Specific But Not Sensitive, Comparison of Structured Versus Abstracted Comorbidities Using Oncology EHR Data from Cancer Patients in the Flatiron Health Network, Oncology Data Abstraction: Leveraging the Clinical Expertise of Oncology Nurses to Unlock Clinical Insights from Data in Electronic Health Records, Identification of Resistance Mechanisms to EGFR Treatment in the Real World Using a Clinicogenomic Database, Use of Cancer Immunotherapies in the Real-World in the Setting of Microsatellite Instability, Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients, Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients Stratified by Tumor Burden, An assessment of KRAS, NRAS, and BRAF testing prior to 1st line of therapy among mCRC patients treated at community cancer centers in the United States, Survival of Chemotherapy (chemo) Refractory Gastric or Gastroesophageal Junction Cancer (GC/GEJC) Patients From Flatiron Health (FH): Matched Clinical Characteristics to ATTRACTION-2 and CHECKMATE-032, Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database, Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database, Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT), Sequencing Therapy in Chronic Lymphocytic Leukemia (CLL): Treatment Patterns and Associated Outcomes in Community Practice for Patients with Relapsed/Refractory CLL in the United States, Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States, Multiple Myeloma Patients and Risk of Skeletal Related Events Real-World Evidence in US Oncology Clinics, Population Characteristics and Utilization Patterns of Patients Treated with Palbociclib Over 2 Years of Post-Approval, Treatment Patterns for Young Women with HR+/HER2- Metastatic Breast Cancer in the United States in the Era of CDK 4/6 Inhibitors, Concordance of Real World Progression Free Survival (PFS) on Endocrine Therapy as First Line Treatment for Metastatic Breast Cancer using Electronic Health Record with Proper Quality Control Versus Conventional PFS from a Phase 3 Trial, Distribution of PD-L1 Tumor Expression By Assay Type in Patients with Metastatic NSCLC (mNSCLC), Utilization and Timing of Foundation Medicine (FMI) Testing in U.S. Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients, Real-World Patient Characteristics, Testing and Treatment Patterns of ALK+ NSCLC, ALK Testing Trends and Patterns Among Community Practices in the United States, Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US, Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States, Immune Checkpoint Inhibitor (ICPI) Efficacy and Resistance Detected by Comprehensive Genomic Profiling (CGP) in Non-Small Cell Lung Cancer (NSCLC), Analyzing Biomarkers of Cancer Immunotherapy (CIT) Response Using a Real-World Clinico-Genomic Database, Treatment Patterns and Clinical Outcomes in Patients with Metastatic Pancreatic Cancer Treated with First-Line Nab-Paclitaxel Plus Gemcitabine: Analysis of US Electronic Health Records from the Flatiron Health Database, Treatment and Outcomes of Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma in the United States, Treatment patterns and clinical outcomes in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: Analysis of US electronic health records from the Flatiron Health Database, Treatment and outcomes of patients with advanced gastric, esophageal, or gastroesophageal junction adenocarcinoma in the United States, Adoption of Immunotherapy into Real World Practice: Insights from the Use of Checkpoint Inhibitors, Racial Disparities in the Use of Programmed Death-1 Checkpoint Inhibitors, Disparities in Next Generation Sequencing in a Population-Based Community Cohort of Patients with Advanced Non-Small Cell Lung Cancer, Development and Validation of a Real-World Clinico-Genomic Database, The Application of Electronic Medical Records (Emrs) As a Virtual Comparator Arm in a Lung Cancer Clinical Trial: a Case Study, Real World Treatment Patterns of First-line Combination Therapies Among Patients with Metastatic Melanoma and BRAF Mutation, Characteristics of Advanced NSCLC Patients Receiving Molecular Diagnostic Testing in US Routine Clinical Practice, Clinical and Demographic Characteristics of Cll Patients Receiving First-line Bendamustine Plus Rituximab Using the Flatiron Health Database, Real-World Treatment Pattern and Discontinuation of Systemic Combination Therapies in Metastatic Melanoma, Evidence of Low Incidence of Myelodysplastic Syndrome (MDS) in Patients Exposed to Bendamustine Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Implementation of the IOM 13 Point Care Plan by OCM Practices, Electronic Calculation of Quality Measures in the EMR is Highly Dependent on Data Capture in Structured Fields: The Oncology Care Model (OCM) Quality Reporting Experience, Rates of PD-L1 Expression Testing in US Community-Based Oncology Practices for Patients with Metastatic Non-Small Cell Lung Cancer Receiving Nivolumab or Pembrolizumab, Retrospective Indirect Comparison of Alectinib Phase II Data vs Ceritinib Real-World Data in ALK+ NSCLC After Progression on Crizotinib, The NCCN-Flatiron Outcomes Database: Collaborative Evidence Development and Quality Improvement in Oncology, Chemotherapy Use Near End of Life (EOL): Measuring Real World Benchmarks, Real-World Concordance of Clinical Practice with ASCO and NCCN Guidelines for EGFR/ALK Testing in aNSCLC, Treatment Sequences in Non-Small Cell Lung Cancer in the United States From 2014-2016, Validation of Diagnosis Codes to Identify Side of Colon in an Electronic Health Record Registry, The Treatment Continuum of Panitumumab, Cetuximab, and Bevacizumab in 1st Through 3rd Line by KRAS, NRAS, and BRAF Mutation Status Among mCRC Patients Treated at Community Cancer Centers in the United States, Real-World Treatment Patterns for Advanced EGFR Wild-type NSCLC in Second Or Third Line in a Large US Database, Bone Targeting Agent Treatment Patterns Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the United States: Observations from Real-World Data, Changing Demographics and Treatment Patterns in Patients in the United States with Chronic Lymphocytic Leukemia in the First-line Setting as Assessed Using a Novel Electronic Health Record Database, Real World Anaplastic Lymphoma Kinase (ALK) Rearrangement Testing Patterns, Treatment Sequences and Survival of ALK-inhibitor Treated Patients, Concomitant use of emerging therapies and bone-targeting agents in prostate cancer: Observations from real-world data, Treatment Patterns for Metastatic Melanoma in US Community Oncology Clinical Practice: A Retrospective Observational Study, Initiation and Adherence with Bone-Targeting Agents in US Men with Bone Metastases from Prostate Cancer, Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort, Assessment of Treatment with Panitumumab, Cetuximab, and Bevacizumab Among mCRC Patients with Wild-Type RAS or BRAF Treated and Community Cancer Centers in the United States, Characterization of KRAS, BRAS, and BRAF Testing and Timing Among mCRC Patients Treated At Community Cancer Centers in the United States, Real-World Bortezomib Usage Patterns Among Patients with Relapsed/Refractory Multiple Myeloma, BRAF, KIT, and NRAS Testing Patterns and Results in Metastatic Melanoma, Improving misclassification of ICD-9 coding for bone metastases in electronic medical records (EMR) using technology-enabled abstraction.

Michael Thomas Wlns Wife, Screwfix Radiator Shelf, Randy Savage Garage Cause Of Death, Articles F